Kosuke Iwasaki joined Milliman’s Tokyo office in 1999 and moved to New York in 2000. As a consulting actuary in healthcare and life insurance, he has contributed to or managed projects with life/health insurance companies, pharmaceutical companies, medical device companies, disease management companies, managed care organizations, and research institutes.
After 13 years in New York, he returned to Milliman’s Tokyo office in July of 2013 to establish the firm’s healthcare and data analytics practice in Japan.
Health technology assessment (HTA) including cost-effectiveness, cost-utilization, and cost-benefit analysis for pharmaceutical companies and medical device companies
Economic value of drugs, including antihypertensive and anti-hyperlipidemic agents, diabetes drugs, hepatitis C drugs, antidepressants, anticancer agents, anticoagulation drugs, and drugs for COPD, hemophilia, and amyotrophic lateral sclerosis
Economic value of bariatric surgery
Economic value of disease management programs and screening
Analysis on adverse drug events for hospitals
Value-based design of health insurance, including the cost-sharing structure of diabetes drugs and chemotherapy for cancer patients
Development of a predictive model for a disease management company in Japan
Development of a predictive model for long-term care cost
Development of budget impact models (BIMs) for drugs for diabetes and hepatitis C patients
Development of benchmarks on outcomes for hospitals
Stochastic modeling, including:
Generalized linear model (GLM)
Survival model
Hierarchal Bayesian model
Bayesian network model
Development of healthcare reform models for accountable care organizations (ACOs)
Development of health insurance products, disability income products, long-term care products, and critical illness products for life and health insurance companies
Pricing and profit testing of insurance policies
Due diligence in M&A of life/health insurance companies
He is a member of the Institute of Actuaries of Japan’s Health Insurance Committee.
We estimated the long-term care expenditures/expense due to bone fractures in Japan using publicly available Japanese government statistical data. The expenses increased over time and were estimated to be about \2 trillion in 2016. Families bore the largest part of the cost burden for long-term care related to fractures.
This study examines combination therapies administered following initial therapy with an angiotensin II receptor blocker in hyperintensive Japanese patients.
This study provides up-to-date information on the demographics, medical treatment and cost status of multiple sclerosis treatment in Japan in almost real-time by using a claims database.
05 March 2014 - by Kosuke Iwasaki, Bruce S. Pyenson
This paper discusses the financial risks associated with hemophilia and outlines the issues for regulators, insurers, and provider organizations financially managing the care for this and other rare and expensive medical conditions.
Evaluating antidepressant formulary access and benefit design should help support effective antidepressant treatments in patients with major depressive disorder.